Anti-BARD1抗体

Cat. Number:

Anti-BARD1抗体KL-4291R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

BRCA1 Associated RINGAnti-BARD1抗体 Domain gene 1 (BARD1) interacts with the N terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N terminal RING motif and the C terminal BRCT domain. The RING motif is a cysteine rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer. BARD1 also plays a role in mediating apoptotic stress and p53 dependent.

Also known as:

BARD-1; Bard1; Bard 1; Anti-BARD1抗体BARD1_HUMAN; BRCA1 associated RING domain 1; BRCA1 associated RING domain gene 1; BRCA1 associated RING domain protein 1; BRCA1-associated RING domain protein 1.

Specificity:

Storage:

Shipped at 4℃, Anti-BARD1抗体Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working Anti-BARD1抗体dilutions must be determined by the end user.